公司简介
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...
关联新闻
- Patients are suing GLP-1 drugmakers over the risk of sudden vision loss. The little-discussed potential risk of popular diabetes and weight-loss drugs is on warning labels outside of the U.S.
Michelle Fennell was sitting at her desk when her right eye started feeling heavy. Suddenly, it was blurry and her peripheral vision waned. It felt like she was looking through a fishbowl, she could s...
- Novo, Orbis sign up to $1.4 billion deal to develop oral drugs
Orbis Medicines said on Thursday it had signed a drug discovery and licensing deal with Novo Nordisk worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases that are traditio...
- Will AI Save the Pharma Industry Billions? Novo's Anthropic Deal Is Betting on It.
Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process.
- Novo CEO urges staff to embrace more customer-focused culture
Novo Nordisk's CEO Mike Doustdar on Tuesday urged employees to be more customer-focused, as the Wegovy maker seeks to regain ground in the fast-growing obesity drug market.
- Novo Nordisk rebrands as 'Novo', announces cultural reset
Novo Nordisk is changing its day-to-day name to 'Novo', and taking a new approach to company culture as it looks to claw back ground in the fierce obesity drug race, the Danish drugmaker said on Mon...
- Novo drops ‘Nordisk' in corporate refresh to take on Lilly in the weight-loss wars
The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.
- Novo Nordisk to Rebrand as Novo
The drugmaker said its new name aims to make it more recognizable to compete in the market for obesity medications.
- Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.